Outer Biosciences says human tissue lived a month outside the body. That is the whole disclosure.

"Over a month" is a duration, not a result ^[1]. It arrived in a profile of the founder, and in that text there is no definition of what viable means, no count of how many samples reached a month, no named measured endpoint, and no outside laboratory that has repeated any of it ^[10]. A duration floor with no denominator is compatible with a robust process and with one lucky biopsy, and the source does not let a reader tell those apart.

What a month would buy, if it survives contact with a protocol, is repeated measurement of the same tissue. The company's stated use is training a model on skin that is still alive ^[3], and a model like that needs the substrate to tolerate being observed and perturbed again and again rather than read once and discarded. Duration is the precondition for that dataset, which is why it is the number the company chose to lead with, and also why the missing sample count matters more than the missing weeks.

The second thing the source establishes is where a working rig would find its first paying use. Outer's chief scientist, Kyung-Jin Jang, sits on the scientific advisory board of Haus Labs, the cosmetics company Stefani Germanotta built, and the two firms have run joint projects ^[5]. Germanotta also sits on Outer's board ^[4]. Haus Labs runs out of El Segundo with roughly 70 employees ^[6]. So the nearest customer for living human skin is a beauty brand with shared personnel and a shared director, and nothing in the material names a drug developer, a contract research organisation, or a regulator that has looked at the tissue. A claim-substantiation job for a related company is a much smaller thing than displacing a preclinical step, and it is the only commercial adjacency the source actually shows.

Polansky is not a scientist and says he came into life sciences accidentally, through more than a decade in cancer immunotherapy alongside Sean Parker ^[7]; he remains executive director of the Parker Institute for Cancer Immunotherapy ^[8], and before that he was a principal at Founders Fund after three years at Bridgewater ^[9]. That biography is relevant in one narrow way: he has unusually good access to people who could independently check a viability claim, and the company spent years keeping the work quiet instead ^[2]. Whatever the tissue does, the disclosure has been engineered for a profile rather than for a reviewer, and that is the part a buyer is being asked to price.